Neurological
Refine Search
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Pharmaceutical
Opioid dependence specialist Indivior and Switzerland’s Addex Therapeutics have announced they will no longer work together on development of ADX71441. 14 February 2019
Pharmaceutical
French drugmaker Ipsen has presented financial results for full-year 2018, showing that group sales grew 16.6% as reported and 20.1% at constant exchange rates to reach 2.22 billion euros ($2.51 billion). 14 February 2019
Pharmaceutical
Australian medicinal cannabis company Althea has announced it is launching a UK-based subsidiary aimed at leveraging its experience as a supplier of cannabis-based pharmaceutical products. 13 February 2019
Pharmaceutical
Japanese drugmaker Eisai has submitted an application to the European Medicines Agency (EMA) for its antiepileptic drug Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy. 13 February 2019
Biotechnology
Roche and Boehringer Ingelheim’s Activase (alteplase) is currently the only treatment of acute ischemic stroke (AIS), but this situation will start to change from 2021, according to GlobalData. 13 February 2019
Pharmaceutical
US healthcare giant Johnson & Johnson has been buoyed by a positive decision from the advisory panel of the US regulator on the firm’s experimental depression therapy Spravato (esketamine). 13 February 2019
Pharmaceutical
Despite 2018’s successes in the neurology market, research and development (R&D) setbacks in the field of Alzheimer’s disease continue to disappoint, a new review concludes. 12 February 2019
Biotechnology
An ongoing open-label extension study treating patients with brain disease drug Brineura (cerliponase alfa) continued to show a reduced rate of decline compared to a natural history cohort of CLN2 disease for three years as measured by the CLN2 Clinical Rating Scale. 11 February 2019
Biotechnology
Coinciding with International Epilepsy Day, UK-based charity The Epilepsy Society and Belgium’s UCB have announced a new collaboration to advance understanding of epilepsy. 11 February 2019
Biotechnology
US biotech firm Neuralstem, focused on the development of cell-based and small molecular therapeutic for central nervous system indications, has announced the initiation of a program to expand its current pipeline of therapeutic products. 8 February 2019
Generics
London-listed addiction specialist Indivior failed in its bid to block a generic competitor to its Suboxone film drug, used in the treatment of opioid addiction. 6 February 2019
Pharmaceutical
Appaloosa, the US hedge fund managed by billionaire David Tepper, has called for major and immediate change at Allergan, the Ireland-based drugmaker that is best known for its Botox (onabotulinumtoxinA) product. 6 February 2019
Pharmaceutical
Lundbeck saw its shares down 4.9% at 272.30 Danish kroner in late morning trading, after it reported financial results for 2018, but noting that it will lower dividends to shareholders. 5 February 2019
Biotechnology
Japanese biotech Sosei Heptares Group has announced an agreement with Medicxi, a venture fund dedicated to financing asset-centric firms, to form two independent companies, Orexia and Inexia. 4 February 2019
Pharmaceutical
Tokyo-based Eisai and development partner Purdue Pharma have announced detailed results from the Phase III SUNRISE 2 study of insomnia candidate lemborexant. 4 February 2019
Pharmaceutical
New clinical trial data featured in the news last week, with Alexion presenting positive Phase III results for its Ultomiris, a follow-on to its current best seller Solaris, and Takeda released encouraging Phase III data on its dengue fever candidate TAK-003. However, another potential Alzheimer’s treatment hit the dust as Roche and AC Immune said they would discontinue development of crenezumab. Deal-making stories included Neurocrine Biosciences entering a strategic collaboration with Voyager Therapeutics on VY-AADC and VY-FXN01 for Parkinson’s disease and Friedreich’s ataxia in an up to $1.7 billion deal. 3 February 2019
Pharmaceutical
Soaring sales of the gastro drug Entyvio (vedolizumab) have helped Takeda to record a rise in profits and revenue for the latest quarter. 1 February 2019
Pharmaceutical
Spain-based specialty drugmaker Neuraxpharm Group, focused on the treatment of central nervous system disorders (CNS), has acquired Farmax. 1 February 2019
Pharmaceutical
US-based Sunovion Pharmaceuticals has been rejected in its bid for approval for apomorphine sublingual film (APL-130277), receiving a Complete Response Letter from the US regulator. 31 January 2019
Pharmaceutical
Shares in Swiss pharma giant Novartis dipped by 1.4% on Wednesday morning as the company announced its fourth quarter and annual financial results. 30 January 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze